Imaging breast cancer response during neoadjuvant systemic therapy

Expert Review of Anticancer Therapy

Volumn 5, Issue 5, 2005, Pages 893-905

  Beresford, Mark ^a   Padhani, Anwar R ^b   Goh, Vicky ^b   Makris, Andreas ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b Paul Strickland Scanner Centre   (United Kingdom)

Author keywords

Breast cancer; Chemotherapy; Mammography; MRI; Neoadjuvant; PET; Response; Spectroscopy; Ultrasound

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; METHOTREXATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TECHNETIUM 99M; VINCRISTINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECHOMAMMOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MAMMOGRAPHY; MEDICAL DECISION MAKING; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN PRESERVATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; TREATMENT PLANNING; TUMOR VASCULARIZATION; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27744565630     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.5.5.893     Document Type: Review

References (84)

1. Hortobagyi GN, Ames FC, Buzdar AU et al. Management of Stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62, 2507-2516 (1988).
2. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res. 43(4), 1488-1492 (1983).
3. Fisher B, Redmond C, Poisson R et al. Eight-year results of a randomised clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med. 320, 822-828 (1989).
4. Veronesi U, Zucali R, Luini A. Local control and survival in early breast cancer: the Milan trial. Int. J. Radiat. Oncol. Biol. Phys. 12(5), 717-720 (1986).
5. Makris A, Powles TJ, Ahsley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann. Oncol. 9(11), 1179-1184 (1998).
6. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15(7), 2483-2493 (1997).
7. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16(8), 2672-2685 (1998).
8. Ellis P, Smith I, Ashley S et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. 16, 107-114 (1998).
9. Bonadonna G, Valagussa P. Brambilla C et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 16, 93-100 (1998).
10. Machiavelli MR. Romero A, Perez JE et al. Prognostic significance of pathological response of primary tumour and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J. Sci Am. 4(2), 125-131 (1998).
11. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project. J. Natl. Cancer Inst. Monogr. 30, 96-102 (2001).
12. Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann. Oncol. 16(2), 267-272 (2005).
13. Kennedy S, Merino MJ, Swain SM, Lippman ME. The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum. Pathol. 21(2), 192-198 (1990).
14. Ferrozzi F, Tognini G, Pavone P. Structural changes induced by antineoplastic therapies: keys to evaluate tumor response to treatment. Eur. Radiol. 12(4), 928-937 (2002).
15. Sharkey FE, Addington SL, Fowler LJ, Page CP, Cruz AB. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod. Pathol. 9(9), 893-900 (1996).
16. Moll UM, Chumas J. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. Pathol. Res. Pract. 193(3), 187-196 (1997).
17. Honkoop AH, Pinedo HM, De Jong JS et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am. J. Clin. Pathol. 107(2), 211-218 (1997).
18. Smith IC, Miller ID. Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs 12(Suppl. 1), S25-S29 (2001).
19. Kuerer HM, Newman LA, Buzdar AU et al. Pathologic tumour response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J. Sci. Am. 4, 230-236 (1998).
20. Ogston KN, Miller ID, Payne S et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12, 320-327 (2003).
21. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 46(5), 2578-2581 (1986).
22. Bottini A, Berruti A, Tampellini M et al. Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease. Tumour Biol. 18(5), 301-310 (1997).
23. Berberoglu U, Yildirim E, Celen O. Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int. J. Biol. Markers 19(2), 130-134 (2004).
24. Moskovic EC, Mansi JL, King DM, Murch CR, Smith IE. Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin. Radiol. 47(5), 339-344 (1993).
25. Cocconi C, Di Blasio B, Alberti G, Bisagni G, Botti E, Peracchia G. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res. Treat. 4(4), 309-313 (1984).
26. Segel MC, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 169(1), 49-54 (1988).
27. Vinnicombe SJ, MacVicar AD, Guy RL et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198(2), 333-340 (1996).
28. Helvie MA, Joynt LK, Cody RL, Pierce LJ, Adler DD, Merajver SD. Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology 198(2), 327-332 (1996).
29. Skaane P, Skjennald A. Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial in a population-based screening program - the Oslo II Study. Radiology 232(1), 197-204 (2004).
30. Lewin JM, D'Orsi CJ, Hendrick RE et al. Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. AJR Am. J. Roentgenol. 179(3), 671-677 (2002).
31. Yang W, Lam WW, Cheung H, Suen M, King WW, Metreweli C. Sonographic, magnetic resonance imaging and mammographic assessments of preoperative size of breast cancer. J. Ultrasound Med. 16, 791-797 (1997).
32. Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin. Cancer Res. 3(9), 1565-1569 (1997).
33. Burcombe R, Wilson GD, Richman PI et al. Comparison of clinical, radiological and pathological assessment of response to neoadjuvant chemotherapy for primary breast cancer. European Cancer Conference, Lisbon, Portugal (2001).
34. Fiorentino C, Berruti A, Bottini A et al. Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res. Treat. 69(2), 143-151 (2001).
35. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC. Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology 190(3), 825-830 (1994).
36. Moyses B, Haegele P, Rodier JF et al. Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer. Clin. Breast Cancer 2(4), 304-310 (2002).
37. Akashi-Tanaka S, Fukutomi T, Watanabe T et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int. J. Cancer 96(1), 66-73 (2001).
38. Akashi-Tanaka Fukutomi T, Sato N et al. The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. Ann. Surg. 239(2), 238-243 (2004).
39. Miles KA. Functional CT imaging in oncology. Eur. Radiol. 13(Suppl. 5), M134-M138 (2003).
40. Sahani DV, Kalva SP, Hamberg LM et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234(3), 785-792 (2005).
41. Khalkhali I, Baum JK, Villanueva-Meyer J et al. Diagnostic accuracy of 99mTc-sestamibi breast imaging: multicenter trial results. J. Nucl. Med. 41(12), 1973-1979 (2000).
42. Cayre A, Cachin F, Maublant J et al. Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. Int. J. Oncol. 20(5), 1049-1055 (2002).
43. Tiling R, Kessler M, Untch M et al. Breast cancer: monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography. Onkologie 26, 27-31 (2003).
44. Esserman L, Hylton N, Yassa L et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J. Clin. Oncol. 17(1), 110-119 (1999).
45. Abraham DC, Jones RC, Jones SE et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78(1), 91-100 (1996).
46. Rieber A, Brambs HJ, Gabelmann A, Heilmann V. Kreienberg R, Kuhn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur. Radiol. 12(7), 1711-1719 (2002).
47. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am. J. Roentgenol. 179(5), 1193-1199 (2002).
48. Warren RM, Bobrow LG, Earl HM et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy. Br. J. Cancer 90, 1349-1360 (2004).
49. Padhani AR, Dzik-Jurasz A. Perfusion MR imaging of extracranial tumour angiogenesis. Top. Magn. Reson. Imaging 15(1), 41-57 (2004).
50. Ah-See ML, Padhani AR. Dynamic magnetic resonance imaging in breast cancer. In: Dynamic Contrast-enhanced Magnetic Resonance Imaging in Oncology. Jackson A, Parker GJM (Eds). Springer-Verlag, Berlin, Germany, 145-174 (2004).
51. Knopp MV, Brix G, Junkermann HJ, Sinn HP. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn. Reson. Imaging Clin. N. Am. 2(4), 633-658 (1994).
52. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 15(2), 154-163 (2002).
53. Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 228(1), 63-69 (2003).
54. Drew PJ, Kerin MJ, Mahapatra T et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur. J. Surg. Oncol. 27(7), 617-620 (2001).
55. Martincich L, Montemurro F, De Rosa G et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res. Treat. 83(1), 67-76 (2004).
56. Padhani AR. Contrast-enhanced MRI to predict clinico-pathological response of breast cancer to primary chemotherapy. Initial clinical results. Mount Vernon Hospital (Middlesex, UK) (2005).
57. Ah-See ML, Makris A, Taylor NJ et al. Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer? In: American Society of Clinical Oncology. LA, USA (2004).
58. Leach MO, Verrill M, Glaholm J et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed 11(7), 314-340 (1998).
59. Redmond OM, Stack JP, O'Connor et al. 31P MRS as an early prognostic indicator of patient response to chemotherapy. Magn. Reson. Med. 25(1), 30-44 (1992).
60. Gribbestad IS, Singstad TE, Nilsen G et al. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J. Magn. Reson. Imaging 8(6), 1191-1197 (1998).
61. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J. Natl Cancer Inst. 94(16), 1197-1203 (2002).
62. Jagannathan NR, Kumar M, Seenu V et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer 84(8), 1016-1022 (2001).
63. Meisamy Bolan PJ, Baker EH et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy - a pilot study at 4 T. Radiology 233(2), 424-431 (2004).
64. Williams K, Williams F, Handley R. Infrared thermometry in the diagnosis of breast disease. Lancet 2, 1378-1381 (1961).
65. Chance B, Nioka Zhang J et al. Breast cancer detection based on incremental biochemical and physiological properties of breast cancers a six-year, two-site study. Acad. Radiol. 12(8), 925-933 (2005).
66. Godavarty A, Thompson AB, Roy A et al. Diagnostic imaging of breast cancer using fluorescence-enhanced optical tomography: phantom studies. J. Biomed. Opt. 9(3), 488-496 (2004).
67. Hawrysz DJ, Sevick-Muraca EM. Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. Neoplasia 2(5), 388-417 (2000).
68. Jakubowski DB, Cerussi AE, Bevilacqua F et al. Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy a case study. J. Biomed. Opt. 9(1), 230-238 (2004).
69. Wahl R, Cody R, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radio-labeled glucose analogue 2-[F-18]-fluoro-D-glucose. Radiology 179, 765-770 (1991).
70. Adler L, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET Radiology 187, 743-750 (1993).
71. Bassa P, Kim EE, Inoue T et al. Evaluation of preoperative chemotherapy using PET with Fluorine-18-fluorodeoxyglucose in breast cancer. J. Nucl. Med. 37, 931-938 (1996).
72. Wahl R, Zasadny K, Helvie M. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J. Clin. Oncol. 11, 2101-2111 (1993).
73. Jansson T, Westlin J, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early evaluation? J. Clin. Oncol. 13, 1470-1477 (1995).
74. Schelling M, Avril N, Nahrig J et al. Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 18, 1689-1695 (2000).
75. Smith IC, Welch AE, Hutcheon AW et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J. Clin. Oncol. 18(8), 1676-1688 (2000).
76. Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of [18F]FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy. Ann. Oncol. 15, 1352-1357 (2004).
77. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur. J. Cancer 38(3), 375-379 (2002).
78. Shields A, Grierson JR, Dohman BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med 4, 1334-1336 (1998).
79. Shields AF, Mankoff DA, Link JM et al. Carbon-11-thymidine and FDG to measure therapy response. J. Nucl. Med. 39(10), 1757-1762 (1998).
80. Vesselle H, Grierson J, Muzi M et al. In vivo vaidation of 3′deoxy-3′-[18F]fluorothymidine as a proliferation imaging tracer in humans: correlation of FLT uptake by positron emission tomography with Ki67 immunohistochemistry and flow cytometry in human lung tissue. Clin. Cancer Res. 8, 3315-3323 (2002).
81. Dittman H, Dohmen BM, Paulsen F et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur. J. Nuc. Med. Mol. Imaging 30(10), 1407-1412 (2003).
82. Smyczek-Gargya B, Fersis N, Dittmann H et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur. J. Nuc. Med. Mol. Imaging 31(5), 720-724 (2004).
83. Buck AK, Halter G, Schirrmeister H. Imaging proliferation in lung tumours with PET: 18F-FLT versus 18F-FDG. J. Nucl. Med. 44, 1426-1431 (2003).
84. Pio B, Park C, Satyamurthy N et al. Monitoring early and long-term effects of breast cancer chemotherapy with fluorodeoxyglucose and fluoro-L-thymidine. In: Society of Nuclear Medicine 50th Annual Meeting 2004. New Orleans, LA, USA.